Bolanos-Meade and colleagues have recently written about the potential use of 5-Azacytidine (5-Aza) without donor lymphocyte infusion in the treatment of 10 patients with myeloid malignancies relapsing after allogeneic BMT, 1 and concluded that 5-Aza was an active agent and induced CR in 6 out of 10 patients. Despite the growing experience with 5-Aza in this setting, 2 --5 there is little information on the use of the other hypomethylating drug, decitabine in the treatment of post-transplant relapsed AML. We report a successful treatment outcome in a 57-year-old male with primary refractory AML who relapsed in extramedullary sites after allo-SCT.
The patient initially presented with circulating blasts and lymph node involvement with AML-M5 subtype. He did not respond to standard 7 þ 3 induction chemotherapy, but did achieve CR after reinduction with high dose ARA-C. He subsequently received high dose melphalan (110 mg/m 2 ) and TBI (1200cGy) myeloablative conditioning followed by a matched-related allo-SCT. He developed grade II acute and chronic GVHD with oral, ocular, skin and liver involvement. Eight months after his transplant, he presented with enlarged, palpable lymph nodes measuring 3 Â 2 cm in the left epitrochlear region and 2 Â 1 cm in the cervical area, which were metabolically active (SUV 2.9--3.4) by position emission tomographycomputed tomography (PET-CT) (Figures 1a and 2a) . Ultrasoundguided biopsy of the epitrochlear lymph node revealed atypical cells; immunostaining was positive for CD34, CD68 and CD117, suggestive of myeloid sarcoma. BM examination remained negative for recurrent AML with 100% donor myeloid and lymphoid chimerism. At the time of his relapse, he had ongoing chronic oral GVHD.
Immunosuppression was discontinued, but led to worsening oral mucosal lichenoid changes, painful ulcerations and elevation of liver function tests. He was treated with methylprednisolone 1 mg/kg per day and tacrolimus, resulting in rapid improvement in liver enzymes and oral GVHD. He was never given a donor lymphocyte infusion. Subsequently, he was initiated on decitabine at a dose of 20 mg/m 2 i.v. daily for 5 days per monthly cycle and concurrently began to taper off his corticosteroid treatment. After the first cycle of decitabine, we observed a significant decrease in the size of his lymph nodes; and after the third cycle, he had no palpable lymph nodes detected on exam. He never had systemic relapse of AML during his follow-up. A PET-CT scan done after the fourth cycle of monthly decitabine therapy revealed complete resolution of the previously noted lesions (Figures 1b and 2b) . His GVHD remained relatively inactive with tapering doses of corticosteroids. After eight cycles of monthly decitabine treatments, he was switched to a bi-monthly schedule because of delay in blood count recovery after subsequent cycles and he has received a total of 13 cycles of therapy with no serious side effects so far. He remains in CR with normal blood counts, and with mild oral and ocular chronic GVHD at 26 months after the extramedullary relapse (EMR) of AML. DISCUSSION EMR of acute leukemia is an ominous sign and generally heralds systemic relapse, which is usually not curable with salvage chemotherapy. 6, 7 The prognosis is especially poor when EMR occurs following a myeloblative allo-SCT, with 2-year OS of only 11 --38%. 7 It has been suggested that leukemia cells, when they are at extramedullary sites, can escape from immune surveillance mechanisms, possibly because of decreased expression of HLA mHAs and adhesion molecules. 8 The finding of EMR in patients with ongoing GVHD may indicate preferential GVL in the BM, while allowing for the evasion of surveillance of leukemic cells in extramedullary sites. 7 Treatment results with systemic chemotherapy, donor lymphocyte infusion or second transplant in these relapsed patients are unsatisfactory because of limited efficacy and generally unacceptable toxicity.
Hypomethylating agents are approved for the treatment of advanced myelodysplastic syndromes, but their anti-leukemic efficacy has been quickly recognized by many investigators. Issa and colleagues 2 at myelodysplastic syndrome (MD) Anderson, reported Phase I trial results on 50 patients with relapsed/ refractory leukemias who were treated with decitabine. The majority of patients had AML/MDS. The overall response rate was 25% with myelosuppression representing the major toxicity.
Graef and colleagues 3 also reported the successful use of 5-Aza in the treatment of relapsed AML after allo-SCT. It was hypothesized that the drug was directly cytotoxic and also augmented the hematologic effect of the donor lymphocyte infusion given concomitantly. On the basis of the hypothesis that hypomethylating agents might increase the GVL effect by inducing leukemic cell differentiation and expression of HLA-DR, Jabbour and colleagues 4 treated 17 patients with 5-Aza for leukemia recurrence after SCT (n ¼ 9, 3 with EMR) or as maintenance (n ¼ 8). Five out of the nine patients responded with three patients achieving CR (lasting 4 months in one and over 17 months in the other two patients). Of the three patients with EMR; one achieved a PR, one died and one achieved a CR.
The use of 5-Aza in the management of post-transplant relapse has been recently presented by the French ATU program. 5 They reported on 29 patients with AML or MDS with disease relapse after allo-SCT. 5-Aza was given at 75 mg/m 2 /day Â 7 days every 4 weeks in the majority of patients. The overall response rate in AML was 22% (5/23 patients) with 3 CRs. Median response duration was 8 months and median OS from time of relapse was 10.5 months. The main adverse effect was febrile neutropenia, seen in 63% of patients; only one case of GVHD exacerbation was noted. There was a trend for better response in the 5-day compared with the 7-day schedule, perhaps pointing to better tolerability and less toxicity with the shorter dosing schedule.
In summary, the case presented here illustrates the significant anti-leukemic effect of decitabine in EMR AML after allo-SCT. It is unlikely that the observed response is attributed to the presence of chronic GVHD as our patient had ongoing GVHD at the time of his relapse. It remains to be determined whether decitabine may also augment a GVL effect.
